7 Amendments of Maria SPYRAKI related to 2019/2816(RSP)
Amendment 48 #
Recital D
D. whereas the excessive and incorrecinefficient use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;
Amendment 60 #
Recital G
G. whereas there is sufficient evidence that action should be taken to reduce the riskenvironmental impact from some pharmaceuticals in substances, which can pose a risk to the environment;
Amendment 77 #
Paragraph 3
3. Notes however with concern the veryTakes note of the soft nature of the measurerecommendations included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution as these are driven by objectives to pursue, whereas the measures to be taken are of member state competence; considers that effective measures are needed to mitigate the impacts of pharmaceuticals in the environment;
Amendment 89 #
Paragraph 5
5. Considers that a holisticmulti-stakeholder approach is needed to tackle pharmaceutical pollutionthe impacts of pharmaceuticals in the environment, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but by designing and implementing a policy mix that combines source-directed, use-oriented and end-of-pipe-measures using a combination of voluntary, economic and regulatory instruments; and also incentiviszing better prescription practices and consumer behaviour;
Amendment 152 #
Paragraph 15
15. Calls on Member States and the Commission to support the research and development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment;
Amendment 202 #
Paragraph 27
27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ healthpharmaceutical consumption should be monitored transparently in order to support and encourage responsible use of medicines based on evidence in order to avoid over- consumption; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;
Amendment 232 #
Paragraph 32
32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is notsuch as environmental monitoring, to adequately and systematically covering the environmental data deficit;